Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, April 3, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that Babette Aicher,\n PhD, Director of Preclinical Development, will be making a poster\n presentation on updated proof-of-concept results for Disorazol Z\n cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian\n and endometrial cancer xenograft models, at the upcoming American\n Association for Cancer Research (\"AACR\") annual meeting, which will be\n held April 6-10, 2013, in Washington D.C. The study is funded through a\n grant from the German Ministry of Education and Research.\n\n\n\n\n\n\n\nAbstract #5476:\n\n\n\"LHRH receptor targeting as mechanism of anti-tumor activity for\n cytotoxic conjugates of Disorazol Z with the LHRH receptor agonistic\n peptide D-Lys6-LHRH\", B. Aicher, T. Schuster, L. Blumenstein, A. Schubert, C. Gruendker,\n J.B. Engel, O. Ortmann, R. Mueller, E. Guenther, M. Gerlach, M. Teifel.\n\n\n\n\nSession:\n\n\nExperimental and Molecular Therapeutics 37\n\n\n\n\nDate & Time:\n\n\nWednesday, April 10, 2013, from 8:00 a.m. to 12:00 p.m. (eastern)\n\n\n\n\nVenue:\n\n\nHall A-C Poster Section 36, Walter E. Washington Convention Center\n\n\n\n\n\n\n\nAbout Disorazol Z \n\n\nDisorazol Z is a novel natural compound, with outstanding cytotoxic\n activity, isolated from the myxobacterium Sorangium cellulosum. Disorazol Z, a macrocyclic polyketide, is produced by a fermentation\n process providing high yield and purity. Besides tubulin binding,\n Disorazol Z has pro-apoptotic properties and has been shown to arrest\n cancer cells in G2 stage of the cell cycle at subnanomolar\n concentrations. Disorazol Z is an ideal partner for the formation of\n cytotoxic conjugates with peptides, proteins, and antibodies to\n selectively target cancer cells.\n\n\nAbout Disorazol Z cytotoxic conjugates such as AEZS-125 and AEZS-138\n\n\nAEZS-125 and AEZS-138 are novel cytotoxic conjugates based on the\n natural compound Disorazol Z and the luteinizing hormone-releasing\n hormone (\"LHRH\") receptor agonist D-Lys6-LHRH. The peptide part directs the conjugates specifically to LHRH\n receptor expressing tumor cells, and mediates binding and uptake via\n endocytosis. Within the cancer cell, the conjugates are cleaved and\n Disorazol Z can deploy its potent...

More updates from Cosciens Biopharma Inc.